DURECT to Participate in Upcoming Healthcare Conferences

           DURECT to Participate in Upcoming Healthcare Conferences

PR Newswire

CUPERTINO, Calif., Sept. 3, 2013

CUPERTINO, Calif., Sept. 3, 2013 /PRNewswire/ --DURECT Corporation (Nasdaq:
DRRX) announced today that management is scheduled to present at three
upcoming healthcare conferences.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  oJames E. Brown, President and CEO, will present at the Rodman and Renshaw
    Conference on Monday, September 9 at 10:00 a.m. Eastern time. The
    conference is being held at the Millenium Broadway Hotel in New York
    City. A live audio webcast of the presentation will be available by
    accessing http://wsw.com/webcast/rrshq23/DRRX.

  oJames E. Brown, President and CEO, will also present at the Stifel
    Nicolaus 2013 Healthcare Conference on Wednesday, September 11 at 3:15
    p.m. Eastern Time. The conference is being held at the Four Seasons Hotel
    in Boston. A live audio webcast of the presentation will be available by
    accessing
    http://www.veracast.com/webcasts/stifel/healthcare2013/21112495487.cfm.

  oMatt Hogan, Chief Financial Officer, will also present at the BioCentury
    Newsmakers in the Biotech Industry Conference on Friday, September 27 at
    2:30 pm Eastern Time. The conference is being held at the Millenium
    Broadway Hotel in New York City. A live audio webcast of the presentation
    will be available by accessing
    http://www.visualwebcaster.com/event.asp?id=95814.

A live audio webcast of these presentations will also be available by
accessing DURECT's homepage at www.durect.com and clicking "Investor
Relations." If you are unable to participate during the live webcast, the
call will be archived on DURECT's website under Audio Archive in the "Investor
Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for
pain and other chronic diseases, with late-stage development programs
including REMOXY^®, POSIDUR^™, ELADUR^®, and TRANSDUR^®-Sufentanil. DURECT's
proprietaryoral, transdermal and injectable depot delivery technologies
enable new indications and superior clinical/commercial attributes such as
abuse deterrence, improved convenience, compliance, efficacy and safety for
small molecule and biologic drugs. For more information, please visit
www.durect.com.

NOTE: POSIDUR^™, SABER^™, ORADUR^®, TRANSDUR^®, ELADUR^® and DURIN^® are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

Website: http://www.durect.com
Contact: Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936